BACKGROUND: It has been shown that Plasmodium falciparum submicroscopic infections (SMI) can contribute to malaria-associated anemia as well as to cerebral malaria. Polymerase chain reaction (PCR) assays are usually used as an alternative to microscopy in detecting subpatently infected individuals. OBJECTIVES: The main objective of this study was to investigate the occurrence of SMI before and after a suppressive antimalarial treatment in the population of the village of Dienga in Gabon. METHODS: Nested PCR was used to detect SMI and to determine genotypes. RESULTS: The prevalence rates of SMI were 13.67% (38/278) at day 0 and 8.99% (25/278) at day 14 after sulfadoxine-pyrimethamine-artesunate treatment. Genotype analysis of two polymorphic regions of the merozoite surface protein (MSP)-1 block 2, MSP-2 and a dimorphic region of the erythrocyte binding antigen (EBA-175) revealed that as many as 88% (22/25) of SMI detected after treatment were completely new alleles, indicating either previously sequestered parasites or newly acquired infections. CONCLUSION: These results demonstrate the usefulness of sulfadoxine-pyrimethamine-artesunate association treatment in the population of Dienga and confirmed early parasite genotype change after a suppressive antimalarial treatment in endemic areas.
BACKGROUND: It has been shown that Plasmodium falciparum submicroscopic infections (SMI) can contribute to malaria-associated anemia as well as to cerebral malaria. Polymerase chain reaction (PCR) assays are usually used as an alternative to microscopy in detecting subpatently infected individuals. OBJECTIVES: The main objective of this study was to investigate the occurrence of SMI before and after a suppressive antimalarial treatment in the population of the village of Dienga in Gabon. METHODS: Nested PCR was used to detect SMI and to determine genotypes. RESULTS: The prevalence rates of SMI were 13.67% (38/278) at day 0 and 8.99% (25/278) at day 14 after sulfadoxine-pyrimethamine-artesunate treatment. Genotype analysis of two polymorphic regions of the merozoite surface protein (MSP)-1 block 2, MSP-2 and a dimorphic region of the erythrocyte binding antigen (EBA-175) revealed that as many as 88% (22/25) of SMI detected after treatment were completely new alleles, indicating either previously sequestered parasites or newly acquired infections. CONCLUSION: These results demonstrate the usefulness of sulfadoxine-pyrimethamine-artesunate association treatment in the population of Dienga and confirmed early parasite genotype change after a suppressive antimalarial treatment in endemic areas.
Authors: G Snounou; X Zhu; N Siripoon; W Jarra; S Thaithong; K N Brown; S Viriyakosol Journal: Trans R Soc Trop Med Hyg Date: 1999 Jul-Aug Impact factor: 2.184
Authors: C T Happi; G O Gbotosho; A Sowunmi; C O Falade; D O Akinboye; L Gerena; D E Kyle; W Milhous; D F Wirth; A M J Oduola Journal: Am J Trop Med Hyg Date: 2004-01 Impact factor: 2.345
Authors: Colin J Sutherland; Ali Alloueche; Jill Curtis; Chris J Drakeley; Rosalynn Ord; Manoj Duraisingh; Brian M Greenwood; Margaret Pinder; David Warhurst; Geoffrey A T Targett Journal: Am J Trop Med Hyg Date: 2002-12 Impact factor: 2.345
Authors: N Elissa; F Migot-Nabias; A Luty; A Renaut; F Touré; M Vaillant; M Lawoko; P Yangari; J Mayombo; F Lekoulou; P Tshipamba; R Moukagni; P Millet; P Deloron Journal: Acta Trop Date: 2003-03 Impact factor: 3.112
Authors: Germán Ramírez-Olivencia; José Miguel Rubio; Pablo Rivas; Mercedes Subirats; María Dolores Herrero; Mar Lago; Sabino Puente Journal: Malar J Date: 2012-09-12 Impact factor: 2.979